SDGR vs CERT vs RXRX vs VEEV vs PFE

For growth investors, Recursion Pharmaceuticals, Inc.

(RXRX) is the stronger pick with 26. 9% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). Pfizer Inc. (PFE) offers the better valuation at 19. 5x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate Schrödinger, Inc. (SDGR) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Pfizer Inc.

(PFE) is the cheapest at 19. 5x versus Veeva Systems Inc. at 30. 9x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 9x.

Over the past 5 years, Pfizer Inc.

(PFE) delivered a total return of -13. 3%, compared to -88. 2% for Recursion Pharmaceuticals, Inc. (RXRX). Over 10 years, the gap is even starker: VEEV returned +519. 4% versus CERT's -83. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pfizer Inc.

(PFE) is the lower-risk stock at 0. 54β versus Recursion Pharmaceuticals, Inc. 's 3. 18β — meaning RXRX is approximately 484% more volatile than PFE relative to the S&P 500. On balance sheet safety, Certara, Inc. (CERT) carries a lower debt/equity ratio of 1% versus 78% for Pfizer Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Recursion Pharmaceuticals, Inc.

(RXRX) is pulling ahead at 26. 9% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: Certara, Inc. grew EPS 86. 7% year-over-year, compared to -3. 5% for Pfizer Inc.. Over a 3-year CAGR, RXRX leads at 23. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Veeva Systems Inc.

(VEEV) is the more profitable company, earning 28. 4% net margin versus -863. 4% for Recursion Pharmaceuticals, Inc. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VEEV leads at 28. 7% versus -867. 9% for RXRX. At the gross margin level — before operating expenses — VEEV leads at 75. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Pfizer Inc.

(PFE) trades at 8. 9x forward P/E versus 19. 0x for Veeva Systems Inc. — 10. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RXRX: 236. 4% to $11. 00.

In this comparison, PFE (6.

5% yield) pays a dividend. SDGR, CERT, RXRX, VEEV do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Pfizer Inc.

(PFE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 54), 6. 5% yield). Recursion Pharmaceuticals, Inc. (RXRX) carries a higher beta of 3. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PFE: +29. 6%, RXRX: -81. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SDGR is a small-cap high-growth stock; CERT is a small-cap quality compounder stock; RXRX is a small-cap high-growth stock; VEEV is a mid-cap high-growth stock; PFE is a mid-cap income-oriented stock. PFE pays a dividend while SDGR, CERT, RXRX, VEEV do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.